References
- Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–436.
- Code of Federal Regulations; 312.32 IND safety reporting. [Internet]. cited 2019 Oct 27. Available from: https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=ac4e0b74c59b8ed33e522992a923917f&mc=true&n=pt21.5.312&r=PART&ty=HTML#se21.5.312_132
- Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64:743–752.
- Center for Drug Evaluation and Research, FDA. Questions and answers on FDA’s Adverse Event Reporting System (FAERS) [Internet]. FDA; 2019 cited 2019 Jul 12. Available from: http://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers
- European Medicines Agency - Pharmacovigilance - EudraVigilance [Internet]. cited 2018 Mar 5. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp.
- Banovac M, Candore G, Slattery J, et al. Patient reporting in the EU: analysis of EudraVigilance data. Drug Saf. 2017;40:629–645.
- Inch J, Watson MC, Anakwe-Umeh S, et al. Patient versus healthcare professional spontaneous adverse drug reaction reporting. Drug Saf. 2012;35:807–818.
- Toki T, Ono S. Spontaneous reporting on adverse events by consumers in the United States: an analysis of the food and drug administration adverse event reporting system database. Drugs Real World Outcomes. 2018;5:117–128.
- Code of Federal Regulations; 314.80 Postmarketing reporting of adverse drug experiences [Internet]. cited 2019 Oct 27. Available from: https://www.ecfr.gov/cgi-bin/text-idx?SID=ac4e0b74c59b8ed33e522992a923917f&mc=true&node=se21.5.314_180&rgn=div8
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI - collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) [Internet]. 2017 cited 2018 Mar 8. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf
- Platt R, Wilson M, Chan KA, et al. The new sentinel network–improving the evidence of medical-product safety. N Engl J Med. 2009;361:645–647.
- Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1–11.
- Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41:143–149.
- Portnoff JM, Lewis DJ. The enigma of pharmacovigilance of patient support programs: a survey of marketing authorization holders in Europe. Ther Innov Regul Sci. 2017;51:486–493.
- European Medicines Agency. Screening for adverse reactions in EudraVigilance [Internet]. cited 2020 May 15. Available from: https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf
- U.S. Food and Drug Administration (FDA). Guidance for industry. Postmarketing adverse experience reporting for human drug and licensed biological products: clarification of what to report [Internet]. cited 2020 May 15. Available from: https://www.fda.gov/media/71635/download
- Harinstein L, Kalra D, Kortepeter CM, et al. Evaluation of postmarketing reports from industry-sponsored programs in drug safety surveillance. Drug Saf. 2019;42:649–655.
- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D [Internet]. cited 2019 Oct 28. Available from: https://database.ich.org/sites/default/files/E2D_Guideline.pdf
- Klein K, Scholl JHG, De Bruin ML, et al. When more is less: an exploratory study of the precautionary reporting bias and its impact on safety signal detection. Clin Pharmacol Ther. 2018;103:296–303.
- Council for International Organizations of Medical Sciences (CIOMS). Current challenges in pharmacovigilance: pragmatic approaches (Report of CIOMS Working Group V). CIOMS; 2001.
- Institute for Safe Medication Practices. ISMP quarter watch: a critique of a key drug safety reporting system [Internet]. 2015 cited 2018 Mar 9. Available from: https://www.ismp.org/quarterwatch/drug-safety-reporting-system.
- Pharmaceutical Industry Associations. Management of safety data originating from patient support and market research programmes [Internet]. cited 2020 May 16. Available from: https://www.ema.europa.eu/en/documents/presentation/presentation-management-safety-data-originating-patient-support-programmes-market-research_en.pdf
- Rolfes L, van Hunsel F, Caster O, et al. Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database: patient reporting and early signal detection. Br J Clin Pharmacol. 2018;84:1514–1524.
- Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Data mining applications in engineering and medicine. InTech; 2012.
- Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539–546.
- Henderson M Disproportionality measures [Internet]. GitHub. cited 2019 Oct 10. Available from: https://github.com/statmike/Disproportionality-Measures-with-SAS
- Ahmed I, Thiessard F, Miremont‐Salamé G, et al. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study. Clin Pharmacol Ther. 2010;88:492–498.
- Hauben M, Patadia V, Gerrits C, et al. Data mining in pharmacovigilance. Drug Saf. 2005;28:835–842.
- Bate A, Lindquist M, Orre R, et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol. 2002;58:483–490.
- Candore G, Juhlin K, Manlik K, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38:577–587.
- Krzanowski WJ, Hand DJ. ROC curves for continuous data [Internet]. CRC Press; 2009. Available from: https://books.google.com/books?id=UZHwdiwOs4QC
- Lin DY, Wei LJ, Ying Z. Checking the cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–572.